{"id":2190,"date":"2013-07-31T11:13:11","date_gmt":"2013-07-31T11:13:11","guid":{"rendered":"\/?p=2190"},"modified":"2013-07-31T11:13:17","modified_gmt":"2013-07-31T11:13:17","slug":"diadexus-inc-otcmktsddxs-still-inching-up-on-strong-volume","status":"publish","type":"post","link":"\/articles\/diadexus-inc-otcmktsddxs-still-inching-up-on-strong-volume\/","title":{"rendered":"diaDexus, Inc. (OTCMKTS:DDXS) Still Inching Up on Strong Volume"},"content":{"rendered":"

\"5DDXS_chart.png\"Yesterday marked another strong trading session for diaDexus, Inc. (OTCMKTS:DDXS<\/a>). The company moved a record volume of nearly 4.5 million shares – an unprecedented number, driven by a huge volume spike in the late afternoon. <\/p>\n

The company’s climb that shot the stock price through the $1.00 mark happened last Thursday, when after months of very low-volume trading, the company shifted nearly 3 million shares and closed 25.9% up. The impetus that possibly aided the sudden jump was a news announcement that informed the public analysts had initiated coverage of the company and attached a ‘strong buy’ rating.<\/p>\n

DDXS<\/a> is a pharmaceutical OTC enterprise with a bit of a difference. Unlike many of their same-tier peers they have a FDA-approved product – their PLAC test that diagnoses increased risk of cardio-vascular disease. Following last week’s major surge, the company posted another press release informing shareholders of an upcoming conference call on Aug 8 when Q2 financial results will be discussed, which possibly helped keep the limelight on DDXS<\/a> and stabilize the price after the jump, with the stock still climbing.<\/p>\n

DDXS<\/a> is doing quite well in 2013, with the stock steadily climbing on the charts and now sitting about three times higher than its January values, following a mostly stable increase with no drastic retraces. The company posted the following financials in its report for Q1 of this year:<\/p>\n